Open AccessAbstract 50: Anti angiogenesis tyrosine kinase inhibitor vandetanib as a radiosensitizer for hepatocellular carcinoma
Author(s) -
Sami Znati
Publication year - 2019
Language(s) - English
Resource type - Conference proceedings
DOI - 10.1158/1538-7445.sabcs18-50
Subject(s) - vandetanib , radiosensitizer , hepatocellular carcinoma , angiogenesis , tyrosine kinase inhibitor , medicine , tyrosine kinase , cancer research , sorafenib , angiogenesis inhibitor , vegf receptors , regorafenib , oncology , pharmacology , radiation therapy , cancer , receptor , colorectal cancer